Molecular study of the PCA3 Gene: Genotypic analysis of PCA3 polymorphism-845G>A and metastatic prostate cancer

Genetic Testing and Molecular Biomarkers

Volumn 16, Issue 5, 2012, Pages 418-422

  Fontenete, Silvia ^a   Nogueira, Augusto ^a   Pina, Francisco ^b   Lobo, Francisco ^a   Fraga, Avelino ^c,d   Calais Da Silva, Fernando ^e   Medeiros, Rui ^a,f,g  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b University of Porto   (Portugal)

^c Military Hospital of Porto D Pedro v   (Portugal)

^d HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^e Hospital of Santo António ^*  (Portugal)

^f UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^g LPCC   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CONTROLLED STUDY; DNA POLYMORPHISM; GENE FUNCTION; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC PROSTATE CANCER; PROSTATE CANCER; PROSTATE CANCER GENE 3; TUMOR GENE;

AGED; ANTIGENS, NEOPLASM; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POLYMORPHISM, GENETIC; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84861509800     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2011.0160     Document Type: Article

References (29)

1. Alberts B, Johnson A, Lewis J, et al. (2002). Molecular Biology of the Cell, Garland Science, New York.
2. Aubin SM, Reid J, Sarno MJ, et al. (2010). PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol 184:1947-1952.
3. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. (1999). DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59:5975-5979.
4. Carroll SB (2008). Evo-devo and an expanding evolutionary synthesis: a genetic theory of morphological evolution. Cell 134:25-36.
5. Conde L, Vaquerizas JM, Santoyo J, et al. (2004). PupaSNP Finder: a web tool for finding SNPs with putative effect at transcriptional level. Nucleic Acids Res 32:W242-248.
6. Damber JE, Aus G (2008). Prostate cancer. Lancet 371:1710-1721.
7. Ellis W J (2010). Editorial comment. J Urol 184:1952.
8. FastSNP (2010). SNP function prediction report. A functional analysis and selection tool for SNP in large scale association study. Available at http://fastsnp.ibms.sinica.edu.tw/OnlineAnalysis/AgentOutput.jsp?taskid= TK41575&objectName = rs544190&RiskType =6#FunctionEffectSummary, accessed April 8 2010.
9. Ferlay J, Autier P, Boniol M, et al. (2007). Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581-592.
10. Ferlay J, Parkin DM, Steliarova-Foucher E (2010). Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765-781.
11. Greenlee RT, Murray T, Bolden S, Wingo PA (2000). Cancer statistics, 2000. CA Cancer J Clin 50:7-33.
12. Hessels D, Schalken JA (2009). The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol 6:255-261.
13. Houlston RS, Webb E, Broderick P, et al. (2008). Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet 40:1426-1435.
14. Jia L, Landan G, Pomerantz M, et al. (2009). Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genet 5: e1000597.
15. Klecka J, Holubec L, Pesta M, et al. (2010). Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis. Anticancer Res 30:665-670.
16. Medeiros R, Morais A, Vasconcelos A, et al. (2002). Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells. Prostate 53:88-94.
17. Medeiros R, Vasconcelos A, Costa S, et al. (2003). Steroid hormone genotypes ARStuI and ER325 are linked to the progression of human prostate cancer. Cancer Genet Cytogenet 141:91-96.
18. Medeiros RM, Morais A, Vasconcelos A, et al. (2002). Outcome in prostate cancer: association with endothelial nitric oxide synthase Glu-Asp298 polymorphism at exon 7. Clin Cancer Res 8:3433-3437.
19. Nakanishi H, Groskopf J, Fritsche HA, et al. (2008). PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 179:1804-1809; discussion 1809-1810.
20. Ribeiro R, Vasconcelos A, Costa S, et al. (2004). Overexpressing leptin genetic polymorphism (-2548 G/A) is associated with susceptibility to prostate cancer and risk of advanced disease. Prostate 59:268-274.
21. Salagierski M, Verhaegh GW, Jannink SA, et al. (2010). Differential expression of PCA3 and its overlapping PRUNE2 transcript in prostate cancer. Prostate 70:70-78.
22. Teixeira AL, Ribeiro R, Cardoso D, et al. (2008). Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clin Cancer Res 14:3367-3371.
23. Teixeira AL, Ribeiro R, Morais A, et al. (2009). Combined analysis of EGF + 61G >A and TGFB1 + 869T >C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility. Pharmacogenomics J 9:341-346.
24. van Gils MP, Hessels D, Hulsbergen-van de Kaa CA, et al. (2008). Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 68:1215-1222.
25. Visel A, Rubin EM, Pennacchio LA (2009). Genomic views of distant-acting enhancers. Nature 461:199-205.
26. Vlaeminck-Guillem V, Ruffion A, André J, et al. (2010). Urinary prostate cancer 3 test: toward the age of reason? Urology 75:447-453.
27. Whitman EJ, Groskopf J, Ali A, et al. (2008). PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 180:1975-1978; discussion 1978-1979.
28. Yang JJ, Cheng C, Yang W, et al. (2009). Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 301:393-403.
29. Zhou W, Chen Z, Hu W, et al. (2011). Association of short tandem repeat polymorphism in the promoter of prostate cancer antigen 3 gene with the risk of prostate cancer. PLoS One 6:e20378.